Molecular Cancer

Table 2 Clinico-pathological characteristics and TRAIL-R2 expression of patients with colorectal carcinoma

From: Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

			High TRAIL-R2		Low TRAIL-R2		p value
	N	%	N	%	N	%
Total Number of Cases	365		217	59.4	148	40.6
Age
< = 50 years	121	33.1	71	58.7	50	41.3	0.8320
> 50 years	244	66.9	146	59.8	98	40.2
Gender
Male	172	47.1	101	58.7	71	41.3	0.7883
Female	193	52.9	116	60.1	77	39.9
Tumour Site
Left colon	309	84.7	195	63.1	114	36.9	0.0009
Right colon	56	15.3	22	39.3	34	60.7
Histological Type
Adenocarcinoma	323	88.5	202	62.5	121	37.5	0.0010
Mucinous Carcinoma	42	11.5	15	35.7	27	64.3
Tumour Stage
I	46	13.3	33	71.7	13	28.3	0.2842
II	117	33.9	65	55.6	52	44.4
III	137	39.7	84	61.3	53	38.7
IV	45	13.0	28	62.2	17	37.8
Differentiation
Well	28	7.7	22	78.6	6	21.4	< 0.0001
Moderate	276	75.6	176	63.8	100	36.2
Poor	61	16.7	19	31.1	42	68.9
KRAS Mutation
Present	67	29.9	41	61.2	26	38.8	0.0481
Absent	157	70.1	117	74.5	40	25.5
K-RAS 2A (cyto)
High expression	160	46.8	128	80.0	32	20.0	< 0.0001
Low expression	182	53.2	82	45.1	100	54.9
Cleaved-Caspase 3
High expression	164	49.8	109	66.5	55	33.5	0.1209
Low expression	165	50.2	96	58.2	69	41.8
P27 (Nuc)
High expression	135	40.2	102	75.6	33	24.4	< 0.0001
Low expression	201	59.8	105	52.2	96	47.8
MSI-Molecular
MSI-H	66	19.8	28	42.4	38	57.6	0.0003
MSI-S/L	267	80.2	178	66.7	89	33.3
Overall Survival
5 Years				67.3		57.6	0.0211

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com